This week, Amol and Rebecca discuss a recent study and an updated recommendation: A multi-centre, randomized control trial (the LEADER trial) examined the cardiovascular effect of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue. Patients with type 2 diabetes and high cardiovascular risk were randomly assigned to receive either standard of care plus liraglutide or standard of ...
The post Motherhood Statements: Cardiovascular Effect of Liraglutide and Syphilis Screening appeared first on Healthy Debate.
